GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (FRA:UKJ) » Definitions » Loans Receivable

Opthea (FRA:UKJ) Loans Receivable : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Opthea Loans Receivable?

Opthea's Loans Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.


Opthea Loans Receivable Historical Data

The historical data trend for Opthea's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Loans Receivable Chart

Opthea Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Opthea Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Opthea Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Opthea Loans Receivable Related Terms

Thank you for viewing the detailed overview of Opthea's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Opthea Business Description

Traded in Other Exchanges
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Opthea Headlines

No Headlines